Sugi Predict

Sugi Predict / Compounds / SCHEMBL4378912

SCHEMBL4378912

SCHEMBL4378912

N#Cc1cnc2cc(O)ccc2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGDS O60760 2/20 0.59
▸ ESR2 Q92731 4/20 0.54
▸ PDGFRB P09619 1/20 0.50
▸ PDGFRA P16234 1/20 0.50
▸ ALDH1A1 P00352 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ CASP1 P29466 1/20 0.46
▸ CASP7 P55210 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ CA9 Q16790 2/20 0.42
▸ CA12 O43570 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ CA3 P07451 1/20 0.42
▸ CA6 P23280 1/20 0.42
▸ CA14 Q9ULX7 1/20 0.42
▸ CDK5 Q00535 3/20 0.39
▸ CDK5R1 Q15078 3/20 0.39
▸ MMP3 P08254 1/20 0.38
▸ MIF P14174 1/20 0.38
▸ TRPV1 Q8NER1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4949489 0.86 HPGDS (0.47) HPGDSESR2PDGFRBPDGFRAALDH1A1
SCHEMBL14894589 0.79 HPGDS (0.59) HPGDSPDGFRBPDGFRAKMT2AHTT
SCHEMBL21689072 0.79 HPGDS (0.59) HPGDSALDH1A1MEN1CASP1KMT2A
SCHEMBL17460812 0.79 HPGDS (0.64) HPGDSALDH1A1MEN1KMT2A
SCHEMBL29697466 0.79 HPGDS (0.59) HPGDSALDH1A1HTTCDC7
SCHEMBL4535704 0.79 HPGDS (0.59) HPGDSALDH1A1HTTCDC7
SCHEMBL6183990 0.79 HPGDS (0.59) HPGDSPDGFRBPDGFRAHTTCDC7
SCHEMBL28203717 0.77 ESR2 (0.66) ESR2PDGFRBPDGFRAALDH1A1MEN1
SCHEMBL27569712 0.76 HPGDS (0.52) HPGDSPDGFRBPDGFRAALDH1A1MEN1
SCHEMBL29788946 0.76 ALDH1A1 (0.57) HPGDSPDGFRBPDGFRAALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10954194-B2 18-20 member bi-polycyclic compounds Haro Pharmaceuticals Inc. (US) 2021-03-23 — — US disclosed
US-10752591-B2 18-20 member bi-polycyclic compounds Haro Pharmaceuticals Inc. (US) 2020-08-25 — — US disclosed
US-10377715-B2 18-20 member bi-polycyclic compounds Haro Pharmaceuticals Inc. (US) 2019-08-13 — — US disclosed
US-20170114019-A1 18-20 MEMBER BI-POLYCYCLIC COMPOUNDS HARO PHARMACEUTICAL INC. 2017-04-27 — — US disclosed
US-20170114019-A1 18-20 MEMBER BI-POLYCYCLIC COMPOUNDS HARO PHARMACEUTICAL INC. 2017-04-27 — — US disclosed
WO-2015188015-A1 18-20 MEMBER BI-POLYCYCLIC COMPOUNDS HARO PHARMACEUTICAL INC. (US) 2015-12-10 — — WO disclosed
US-8492560-B2 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2013-07-23 — — US disclosed
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors STOKES ELAINE S E (GB) 2012-08-02 — — US disclosed
EP-2050744-A1 Quinazoline derivatives as angiogenesis inhibitors AstraZeneca AB (SE) 2009-04-22 — — EP disclosed
US-7501516-B2 Quinoline derivatives and their use as tyrosine kinase inhibitors ASTRAZENECA AB (SE) 2009-03-10 — — US disclosed
EP-1154774-B1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2005-06-22 — — EP disclosed
US-20050009867-A1 Quinoline derivatives and their use as tyrosine kinase inhibitors ASTRAZENECA AB (SE) 2005-01-13 — — US disclosed
EP-1409481-A1 QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS Astrazeneca AB (SE) 2004-04-21 — — EP disclosed
CN-1121391-C Substituted 3-cyano quinolines AMERICAN CYANAMID CO (US) 2003-09-17 — — CN disclosed
WO-2003047582-A1 QUINOLINE DERIVATIVES AS ANTITUMOUR AGENTS ASTRAZENECA AB (SE) 2003-06-12 — — WO disclosed
WO-2003008409-A1 QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS ASTRAZENECA AB (SE) 2003-01-30 — — WO disclosed
EP-1154774-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2001-11-21 — — EP disclosed
WO-2000073273-A1 PROCESS FOR THE PREPARATION OF 2-HALO-3-(3-QUINOLYL)PROPIONIC ACID DERIVATIVES NIPPON CHEMIPHAR CO., LTD. (JP) 2000-12-07 — — WO disclosed
WO-2000047212-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2000-08-17 — — WO disclosed
CN-1259125-A Substituted 3-cyanoquinolines AMERICAN CYANAMID CO (US) 2000-07-05 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10752591-B2 18-20 member bi-polycyclic compounds TNNI3, TNNC1, MYLK2 HPGDS 1491/4885ESR2 2416/4885PDGFRB 26/4885
US-10377715-B2 18-20 member bi-polycyclic compounds CKMT1A; CKMT1B, MYLK2, CPT1B HPGDS 1685/4885ESR2 1231/4885PDGFRB 1631/4885
US-10954194-B2 18-20 member bi-polycyclic compounds BRCA1, UGT2B17, TP53 HPGDS 1201/4885ESR2 1337/4885PDGFRB 2744/4885
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors VEGFA, FLT1, KDR HPGDS 434/4885ESR2 4128/4885PDGFRB 125/4885
US-20170114019-A1 18-20 MEMBER BI-POLYCYCLIC COMPOUNDS CKMT1A; CKMT1B, MYLK2, CPT1B HPGDS 1685/4885ESR2 1231/4885PDGFRB 1631/4885
US-20050009867-A1 Quinoline derivatives and their use as tyrosine kinase inhibitors ABL1, FLT3, JAK2 HPGDS 3124/4885ESR2 3199/4885PDGFRB 381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.